Eledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Financial Officer Hires
Jeff Bornstein, M.D. to serve as Chief Medical Officer and Paul Little as Chief Financial OfficerIRVINE, Calif., March 15, 2021...
Staff
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Wellframe Announces Peer-Reviewed Research Highlighting the Positive Impact of Digital Care Management
The Journal of Medical Economics shows that implementing Wellframe reduced inpatient admissions by 17%BOSTON, March 15, 2021 (GLOBE NEWSWIRE) --...
Extendicare Announces March 2021 Dividend of C$0.04 per Share
MARKHAM, Ontario, March 15, 2021 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has...
Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development...
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model
-- BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse -- -- Potential to reduce continued...
ORYZON Announces Successful Pre-IND Meeting with FDA for the Clinical Development of Vafidemstat in Borderline Personality Disorder
Oryzon will consequently proceed to file an IND applicationPORTICO will be developed in several US and European sites MADRID, Spain...
Resonant Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
2020 Revenues Increase Over 330% Year-over-Year to Record $3.2 Million Murata Confirms XBAR® Performance and Moves Into Manufacturing Development Phase...
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which...
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
Novel UCSF investigator led Phase 2 clinical study to address role of epigenetic therapy in mitigating resistance to immune-oncology drugsCALGARY,...
Key partnership for Semeon Analytics Inc. and Adexflow opens new international markets
MONTREAL, March 15, 2021 (GLOBE NEWSWIRE) -- Semeon Analytics, an ATW Tech Inc. company, and Adexflow international are joining forces...
IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation
SAINT LAURENT, Quebec, and NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Corporation”) today...
Recce Pharmaceuticals Announces The Pew Charitable Trusts’ Addition of Recce’s Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development
Filter Drugs By Development Phase and Type RECCE® 327 (R327) has been added to The Pew Charitable Trusts’ annual list...
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs,...
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Completion of balstilimab BLA filing on target for 1H 2021New clinical data for AGEN1181 to be presented at AACRTIGIT bispecific...
MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors
WESTLAKE VILLAGE, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in...
Blueberries Medical Enters Growing Peruvian Medical Cannabis Market: Enters Binding LOI with Futura Farms
TORONTO, March 15, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"),...
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse...
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications
Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib...
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...